United Therapeutics Retained Earnings increased by 3.2% to $8.83B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 17.1%, from $7.54B to $8.83B. Over 5 years (FY 2020 to FY 2025), Retained Earnings shows an upward trend with a 17.4% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
An increase signals strong historical profitability and reinvestment, while a decrease may indicate losses or significant dividend payouts.
This represents the cumulative net income earned by the company since its inception, minus any dividends paid to shareho...
A key metric for all established companies; growth rates are compared against peers to gauge long-term success.
retained_earnings| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $4.04B | $4.20B | $4.32B | $4.55B | $4.67B | $4.91B | $5.04B | $5.28B | $5.54B | $5.81B | $6.03B | $6.33B | $6.61B | $6.92B | $7.22B | $7.54B | $7.85B | $8.19B | $8.56B | $8.83B |
| QoQ Change | — | +4.0% | +2.7% | +5.6% | +2.5% | +5.1% | +2.7% | +4.8% | +4.9% | +4.8% | +3.7% | +5.1% | +4.4% | +4.7% | +4.4% | +4.5% | +4.1% | +4.3% | +4.4% | +3.2% |
| YoY Change | — | — | — | — | +15.6% | +16.8% | +16.9% | +16.0% | +18.7% | +18.3% | +19.5% | +19.9% | +19.3% | +19.1% | +19.8% | +19.1% | +18.8% | +18.4% | +18.5% | +17.1% |